Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Libtayo
Biotech
ASCO: Regeneron misses mark with one CR in solid tumor trial
With analysts looking for an increase in responses for Regeneron's phase 1/2 solid tumor trial, a fresh data slice shows just one complete response.
Gabrielle Masson
May 23, 2024 5:00pm
Replimune shares halve as skin cancer drug fails phase 2
Dec 5, 2023 10:35am
Regeneron rethinks CD28 bispecific R&D plan after 2 patients die
Aug 3, 2023 8:09am
Have mRNA cancer vaccines arrived? Biopharma execs weigh in
Jan 25, 2023 10:30am
BioNTech-Regeneron add 3rd tumor type to cancer vaccine research
Mar 8, 2022 11:47am
